News

Article

NeurologyLive® Friday 5 — March 7, 2025

Key Takeaways

  • Emerging trends in multiple sclerosis are highlighted at the 2025 ACTRIMS Forum, focusing on innovative tracks and clinical insights.
  • FDA approval of suzetrigine introduces a selective, nonaddictive alternative to opioids for acute pain management.
SHOW MORE

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 7, 2025.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Paramagnetic Rim Lesions and Immune Profiling in Multiple Sclerosis Progression: Simon Thebault, MD, PhD

The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]

Paramagnetic Rim Lesions and Immune Profiling in Multiple Sclerosis Progression: Simon Thebault, MD, PhD

2: Detecting Progression in Multiple Sclerosis With Wearables and Imaging: Jacqueline Nicholas, MD, MPH

At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]

Detecting Progression in Multiple Sclerosis With Wearables and Imaging: Jacqueline Nicholas, MD, MPH

3: Clinically Relevant Challenges and Roadblocks of Gene Therapies for Muscular Dystrophies: John Brandsema, MD

The pediatric neurologist at Children’s Hospital of Philadelphia gave perspective on some of the main issues the clinical community is figuring out with gene therapies and their integration to clinical practice. [WATCH TIME: 3 minutes]

Clinically Relevant Challenges and Roadblocks of Gene Therapies for Muscular Dystrophies: John Brandsema, MD

4: NeuroVoices: Rosanna Ricafort, MD, on Early Promise of CAR T-Cell Therapy CD19-XT in Multiple Sclerosis

The vice president and senior global program lead for Hematology and Cell Therapy at BMS gave clinical commentary on encouraging phase 1 findings of CD19-XT in progressive and relapsing multiple sclerosis.

NeuroVoices: Rosanna Ricafort, MD, on Early Promise of CAR T-Cell Therapy CD19-XT in Multiple Sclerosis

5: Furthering the Conversation of Treatment Personalization in NMOSD: Tammy Smith, MD, PhD

The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]

Furthering the Conversation of Treatment Personalization in NMOSD: Tammy Smith, MD, PhD

Related Videos
Crystal Proud, MD  (Credit: Children’s Hospital of the King’s Daughters)
1 expert in this video
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.